#United States #Los Angeles #Nervonik #Neuromodulation #Peripheral Nerve Stimulation

Nervonik Secures $52.5 Million in Series B Financing

Nervonik, Inc., a forward-thinking medical device company specializing in next-generation peripheral nerve stimulation (PNS) technologies, proudly announced the successful closing of an oversubscribed $52.5 million Series B financing round. This significant funding, primarily led by Amzak Health, saw participation from notable firms including Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital.

The fresh capital will primarily be allocated towards advancing Nervonik’s PNS system, with a particular focus on enhancing its proprietary sensing capabilities. This advancement reflects the company's commitment to developing an innovative neuromodulation platform that promises to integrate state-of-the-art stimulation with advanced sensory technology, facilitating a more precise and personalized therapeutic experience for patients. The goal is clear: to provide intelligent, next-generation therapies to those who require them the most.

Aydin Babakhani, CEO and Founder of Nervonik, stated, "We are committed to building a fundamentally differentiated neuromodulation platform that not only focuses on stimulation but also incorporates real-time physiological feedback, crucial for personalizing therapy and enhancing efficacy." This advanced approach allows for the successful recording of evoked compound action potentials (ECAPs) and other essential biomarkers, positioning Nervonik as a leader in the bioelectronic medicine sector.

Initial data from clinical applications indicate promising results, showcasing the technology's ability to effectively customize treatments based on individual patient needs. Anthony Natale, MD, a partner at Amzak Health, underlined the potential of Nervonik’s technology, stating that the field of peripheral nerve stimulation is at a crucial juncture in its evolution. With a growing body of clinical evidence supporting its application in chronic pain management, the advancement of Nervonik’s platform is poised to make a significant impact on patient care.

Dr. Natale expressed his excitement about leading the financing round, emphasizing, "Aydin and the Nervonik team have developed a highly distinct technology platform that has the potential to greatly improve the patient experience. We are enthusiastic about supporting the company through its next growth phase."

Founded and headquartered in Los Angeles, California, Nervonik, Inc. is on a mission to innovate in the medical device landscape with a focus on neuromodulation technologies. The company integrates advanced sensing and stimulation techniques aimed at delivering precision therapies for chronic pain and a variety of neurological conditions. With this newly acquired funding, Nervonik aims to propel its clinical programs forward and prepare for the commercialization phase of its groundbreaking therapies.

The future looks promising for Nervonik, as it stands ready to redefine treatment paradigms within the medical community and deliver transformative solutions to patients in need of effective pain management.